Share this article

VeChain to Develop Drug-Tracing Platform for Pharma Giant Bayer

Bayer China is tapping VeChain to help it track clinical trial drugs along the blockchain.

Updated Sep 14, 2021, 8:45 a.m. Published May 28, 2020, 2:13 p.m.
Credit: Shutterstock/testing
Credit: Shutterstock/testing

One of the largest pharmaceutical companies in the world is working with VeChain to develop a new blockchain-based traceability platform.

STORY CONTINUES BELOW
Don't miss another story.Subscribe to the The Protocol Newsletter today. See all newsletters

Bayer China revealed in an interview Thursday it had chosen VeChain as tech provider for a new blockchain-powered solution that will allow the firm – a branch of Bayer – to track clinical drugs across the supply chain.

Known as "CSecure," the system loads a batch number relating to a specific drug onto the blockchain. Each drug can then be tracked as it moves across the supply chain, using timestamps and user-identification information at different waypoints. Because of the immutable nature of the blockchain, the data can't be changed by a non-permissioned third party.

Also see: IBM, Merck Declare FDA-Backed Drug Tracing Blockchain a Success

VeChain won the right to work with Bayer China in a competition back in 2019, after it proposed the company consider implementing a blockchain-based supply chain solution. The proposal subsequently went on to become CSecure.

The system is based on ToolChain, a proprietary blockchain-as-a-service (BaaS) system that allows VeChain to design and build full distributed ledger technology solutions to a client's specific requirements.

Bayer China is the latest in a series of high-profile partnerships for the blockchain project. Last June, the Chinese arm of supermarket chain Walmart, as well as Big Four accountancy firm PwC teamed up with VeChain to work on a new food tracking solution for China.

However, VeChain isn't saying much about the latest deal. A spokesperson told CoinDesk that the firm is bound by a non-disclosure agreement (NDA) and can't divulge further information about how CSecure would actually work "under the hood."

See also: VeChain Foundation Hacked for $6.5M in VET Token Theft

A statement from CEO and co-founder Sunny Lu did say he was grateful Bayer put VeChain through its paces in testing CSecure's product design.

“We’ve experienced the rigorousness of the medical industry by working with Bayer China," he said. "I feel Bayer’s professionalism and superb work ethic towards medicine and healthcare causes as a whole."

Last year, Uganda’s president backed a similar tracking project from MediConnect that was to use blockchain tech to fight the issue of counterfeit medicines.

More For You

KuCoin Hits Record Market Share as 2025 Volumes Outpace Crypto Market

16:9 Image

KuCoin captured a record share of centralised exchange volume in 2025, with more than $1.25tn traded as its volumes grew faster than the wider crypto market.

What to know:

  • KuCoin recorded over $1.25 trillion in total trading volume in 2025, equivalent to an average of roughly $114 billion per month, marking its strongest year on record.
  • This performance translated into an all-time high share of centralised exchange volume, as KuCoin’s activity expanded faster than aggregate CEX volumes, which slowed during periods of lower market volatility.
  • Spot and derivatives volumes were evenly split, each exceeding $500 billion for the year, signalling broad-based usage rather than reliance on a single product line.
  • Altcoins accounted for the majority of trading activity, reinforcing KuCoin’s role as a primary liquidity venue beyond BTC and ETH at a time when majors saw more muted turnover.
  • Even as overall crypto volumes softened mid-year, KuCoin maintained elevated baseline activity, indicating structurally higher user engagement rather than short-lived volume spikes.

More For You

Deus X CEO Tim Grant: We aren't replacing finance; we're integrating it

Deus X CEO Tim Grant (Deus X)

The Deus X CEO discussed his journey into digital assets, the company's infrastructure-led growth strategy, and why his Consensus Hong Kong panel promises "real talk only."

What to know:

  • Tim Grant entered crypto in 2015 after early exposure to Ripple and Coinbase, drawn by blockchain’s ability to improve traditional finance rather than replace it.
  • Deus X combines investing and operating to build regulated digital finance infrastructure across payments, prime services, and institutional DeFi.
  • Grant will be speaking at Consensus Hong Kong in February.